July 18th 2024
Patrick Boland, MD, discussed the practice-changing implications of the phase 3 ESOPEC study comparing FLOT vs CROSS regimens for the treatment of esophageal adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Takeaways From CheckMate-649 in Gastric/GEJ/Esophageal Cancers
July 14th 2022Ryan Sugarman, MD, discusses the key takeaways from the CheckMate-649 trial of patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma receiving nivolumab combined with chemotherapy compared with chemotherapy alone in the first-line.
Watch
Durvalumab Added to Standard Chemotherapy Prolongs OS in Advanced Biliary Tract Cancer
July 6th 2022In the phase 3 TOPAZ-1 trial, the addition of durvalumab to standard-of-care chemotherapy achieved a statistically significant improvement in overall survival compared chemotherapy alone, meeting the study's primary end point.
Read More
Frontline Tislelizumab Plus Chemo Achieves 34% Reduction in Risk of Death in Advanced ESCC
July 1st 2022In the RATIONALE 306 clinical trial, the combination of tislelizumab and chemotherapy achieved a 34% reduction in the risk of death in patients with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma with either high or low PD-L1 expression.
Read More
Dostarlimab Achieves High Complete Response Rate in Patients with dMMR Rectal Cancer
June 14th 2022Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor in patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.
Read More
FOLFOXIRI Plus Bevacizumab Shows Positive Efficacy But Increased Toxicity in CRC Liver Metastases
June 7th 2022Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.
Read More
Nimotuzumab Plus Chemotherapy Extends OS in KRAS Wild-Type Advanced Pancreatic Cancer
June 3rd 2022The combination of nimotuzumab and gemcitabine extended overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct
Read More
FDA Approves Two Nivolumab Combinations Unresectable Advanced ESCC
May 27th 2022The FDA has granted approval to nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Read More
Data Support Use of Pembrolizumab as Frontline Treatment for MSI-H/dMMR mCRC
May 10th 2022Although there was no significant overall survival benefit shown with pembrolizumab in the KEYNOTE-177 study, response and safety findings still support its use as a frontline option for patients with microsatellite instability high and mismatch repair deficient metastatic colorectal cancer.
Read More
Dosing of KIN-3248 Begins in Advanced Solid Tumors With FGFR2 and/or FGFR3 Alterations
May 2nd 2022The first patient has been dosed in the phase 1 KN-4802 trial examining the safety, tolerability, and preliminary efficacy of KIN-3248 in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.
Read More
Tislelizumab Prolongs OS in Treatment Naïve Patients With Advanced/Metastatic ESCC
April 27th 2022In RATIONALE 306, tislelizumab plus chemotherapy extended overall survival in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
Read More